Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation (HHT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03942315|
Recruitment Status : Completed
First Posted : May 8, 2019
Last Update Posted : May 8, 2019
|Condition or disease||Intervention/treatment|
|Hereditary Haemorrhagic Telangiectasia Liver Transplant||Other: Data collection from standard follow-up after liver transplant|
|Study Type :||Observational|
|Actual Enrollment :||14 participants|
|Official Title:||Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation: Clinical Implications and Physiopathological Insights.|
|Actual Study Start Date :||January 1, 2011|
|Actual Primary Completion Date :||February 1, 2018|
|Actual Study Completion Date :||December 1, 2018|
Liver transplant in Hereditary Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
Other: Data collection from standard follow-up after liver transplant
All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.
- Change in graft status after liver transplant for Hereditary Haemorrhagic Telangiectasia (HHT) (risk of recurrence) [ Time Frame: Every 6 months after transplantation up to 5 years ]Recurrent clinical examinations (including laboratory, histological and radiological investigations)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03942315
|Principal Investigator:||Jérôme DUMORTIER, MD||Hospices Civils de Lyon (Hôpital Edouard Herriot )|